Search Result

Results for "

insomnia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (6) Cytochrome P450 (7) Dopamine Receptor (2) Drug Derivative (2) Drug Intermediate (1) Drug Metabolite (3) Endogenous Metabolite (4) GABA Receptor (8) Histamine Receptor (11) iGluR (2) Isotope-Labeled Compounds (6) MCHR1 (GPR24) (1) Melatonin Receptor (5) Neurokinin Receptor (1) Opioid Receptor (2) Orexin Receptor (OX Receptor) (16) Phospholipase (1) PTEN (1) Reference Standards (12) Sigma Receptor (1) Tryptophan Hydroxylase (2)
By Research Areas:	Cancer (5) Endocrinology (6) Inflammation/Immunology (2) Metabolic Disease (10) Neurological Disease (53)

By Targets:

5-HT Receptor (6)

Cytochrome P450 (7)

Dopamine Receptor (2)

Drug Derivative (2)

Drug Intermediate (1)

Drug Metabolite (3)

Endogenous Metabolite (4)

GABA Receptor (8)

Histamine Receptor (11)

iGluR (2)

Isotope-Labeled Compounds (6)

MCHR1 (GPR24) (1)

Melatonin Receptor (5)

Neurokinin Receptor (1)

Opioid Receptor (2)

Orexin Receptor (OX Receptor) (16)

Phospholipase (1)

PTEN (1)

Reference Standards (12)

Sigma Receptor (1)

Tryptophan Hydroxylase (2)

By Research Areas:

Cancer (5)

Endocrinology (6)

Inflammation/Immunology (2)

Metabolic Disease (10)

Neurological Disease (53)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-A0014

Ramelteon Maximum Cited Publications 12 Publications Verification TAK-375	Melatonin Receptor	Neurological Disease Endocrinology Cancer
Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation .

HY-139559

Vornorexant ORN-0829; TS-142	Orexin Receptor (OX Receptor)	Neurological Disease
Vornorexant (ORN-0829; TS-142) is a potent dual OX1R and OX2R antagonist with IC50 values of 1.05 nM and 1.27 nM, respectively. Vornorexant exhibits potent sleep-promoting effects in vivo and can be used for insomnia research research.

HY-109012

Seltorexant 3 Publications Verification JNJ-42847922	Orexin Receptor (OX Receptor)	Neurological Disease Endocrinology
Seltorexant (JNJ-42847922) is an orally active, high-affinity, and selective orexin-2 receptor (OX2R) antagonist (pK_i values of 8.0 and 8.1 for human and rat OX2R). Seltorexant (JNJ-42847922) crosses the blood-brain barrier and quickly occupies OX2R binding sites in the rat brain .

HY-N0659

Jujuboside A 4 Publications Verification	GABA Receptor	Neurological Disease
Jujuboside A is a glycoside extracted from Semen Ziziphi Spinosae, a Chinese herbal medicine used to treat insomnia and anxiety.

HY-101456

PCPA methyl ester hydrochloride 5 Publications Verification 4-Chloro-DL-phenylalanine methyl ester hydrochloride	Tryptophan Hydroxylase 5-HT Receptor	Neurological Disease
PCPA methyl ester hydrochloride (4-Chloro-DL-phenylalanine methyl ester hydrochloride), a reversible tryptophan hydroxylase inhibitor, is a serotonin (5-HT) synthesis inhibitor. PCPA methyl ester hydrochloride crosses the blood brain barrier and reduces 5-HT central availability .

HY-129105

Clomethiazole 4 Publications Verification	GABA Receptor Cytochrome P450	Neurological Disease
Chlormethiazole is an potent and orally active GABA_A agonist . Chlormethiazole inhibits cytochrome P450 isoforms: CYP2A6 and CYP2E1 in human liver microsomes. Chlormethiazole is an anticonvulsant agent and has the potential for treating convulsive status epilepticus .

HY-19914

MK-1064 3 Publications Verification	Orexin Receptor (OX Receptor)	Endocrinology Cancer
MK-1064 is a selective and orally active OX₂R antagonist (K_i: 0.5 nM, IC₅₀: 18 nM). MK-1064 promotes sleep in vivo. MK-1064 can be used in the research of insomnia .

HY-109012A

Seltorexant hydrochloride 3 Publications Verification JNJ-42847922 hydrochloride	Orexin Receptor (OX Receptor)	Neurological Disease Metabolic Disease
Seltorexant hydrochloride (JNJ-42847922 hydrochloride) is an orally active, high-affinity, and selective OX2R antagonist (pK_i values of 8.0 and 8.1 for human and rat OX2R). Seltorexant hydrochloride crosses the blood-brain barrier and quickly occupies OX2R binding sites in the rat brain .

HY-152843

Fazamorexant YZJ-1139	Orexin Receptor (OX Receptor)	Neurological Disease
Fazamorexant (YZJ-1139) is an orally active dual orexin receptor antagonist, with an IC₅₀ of 32 nM against OX1R and an IC₅₀ of 41 nM against OX2R. Fazamorexant prolongs total sleep time and improves sleep efficiency. Fazamorexant is applicable to related research on insomnia .

HY-A0069

Doxylamine succinate	Histamine Receptor Cytochrome P450	Neurological Disease Metabolic Disease
Doxylamine succinate is a first-generation antihistamine and acts as a histamine H1 receptor antagonist. Doxylamine succinate is orally active, possessing analgesic and hypnotic activities. Doxylamine succinate enhances the activities of CYP2B, CYP2A, CYP3A and thyroxine-glucuronosyltransferase via promoting substrate hydroxylation and thyroxine metabolic pathways. Doxylamine succinate decreases serum thyroxine (T4) level and elevates serum thyroid-stimulating hormone (TSH) level. Doxylamine succinate induces liver enlargement and increases the activities of hepatic microsomal cytochrome P450, cytochrome b5 and NADPH-cytochrome c reductase. Doxylamine succinate can be used for the research of nausea, allergy, insomnia .

HY-W050162

(E)-3,4,5-Trimethoxycinnamic acid 1 Publications Verification TMCA	GABA Receptor 5-HT Receptor	Neurological Disease
(E)-3,4,5-Trimethoxycinnamic acid (TMCA) is a cinnamic acid substituted by multi-methoxy groups. (E)-3,4,5-Trimethoxycinnamic acid is an orally active and potent GABA_A/BZ receptor agonist. (E)-3,4,5-Trimethoxycinnamic exhibits favourable binding affinity to 5-HT_2C and 5-HT_1A receptor, with IC₅₀ values of 2.5 and 7.6 μM, respectively. (E)-3,4,5-Trimethoxycinnamic acid shows anticonvulsant and sedative activity. (E)-3,4,5-Trimethoxycinnamic acid can be used for the research of insomnia, headache and epilepsy .

HY-U00051

Propiomazine	Histamine Receptor Dopamine Receptor	Neurological Disease
Propiomazine is an orally active antihistamine agent. Propiomazine is a potent prolactin (PRL) release stimulant, whose effect depends on the antagonism of the dopaminergic system and can inhibit the secretion of luteinizing hormone (LH). Propiomazine is mainly used for anesthesia assistance, mental disorders and anxiety-induced sedation, and can also be used in research related to insomnia .

HY-101834

ACT-462206	Orexin Receptor (OX Receptor)	Others
ACT-462206 is an orally active and potent dual Orexin 1/Orexin 2 receptor antagonist with IC₅₀s of 60 nM (Orexin 1) and 11 nM (Orexin 2), respectively. ACT-462206 exhibits brain penetration properties, and can be used for insomnia, stress/anxiety-related disorders and addiction research .

HY-A0014S1

Ramelteon-d3 TAK-375-d₃	Melatonin Receptor	Others
Ramelteon-d₃ (TAK-375-d₃) is a deuterium-labelled Ramelteon (HY-A0014). Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with K_i values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation.

HY-P1341

OXA(17-33) Orexin A (17-33) (human, mouse, rat, bovine)	Orexin Receptor (OX Receptor) Sigma Receptor Phospholipase	Neurological Disease
OXA (17-33) (Orexin A (17-33) (human, mouse, rat, bovine)) is the shortest active orexin peptide that selectively targets OX1 (EC₅₀=8.29 nM), with 23-fold selectivity for the OX1 receptor over the OX2 receptor. The activity of OXA (17-33) depends on the Tyr17, Leu20, Asn25, His26 residues and the spatial conformation of the α-helix. OXA (17-33) activates signaling pathways involving inositol-1,4,5-trisphosphate receptor (IP3R), phospholipase D (PL-D) and choline-Sigma-1R, thereby increasing the cytoplasmic Ca ²⁺ level in nucleus accumbens neurons, an effect that is blocked by Sigma-1R antagonists. OXA (17-33) serves as an important biological probe for investigating the function of the OX1 receptor. OXA (17-33) can be modified via incorporation of mixed disulfide bonds of homocysteine and cysteamine, and is widely used in studies related to insomnia and narcolepsy .

HY-106246

Pruvanserin EMD 281014 free base; LY 2422347	5-HT Receptor	Neurological Disease Metabolic Disease
Pruvanserin (EMD 281014 free base) is a selective 5-HT2A receptor antagonist. Pruvanserin alleviates tactile allodynia in diabetic rats. Pruvanserin can also be used for research of insomnia .

HY-106547

Rilmazafone	GABA Receptor	Neurological Disease
Rilmazafone (450191S) is an orally active sleep inducer. Rilmazafone targets cytochrome P-450b and cytochrome P-450e. Rilmazafone induces hepatic drug-metabolizing enzyme activity in rats, mice and dogs. Rilmazafone is applicable for insomnia-related research .

HY-139583

Sunobinop S 117957; IMB 115	Opioid Receptor	Neurological Disease
Sunobinop (S 117957; IMB 115) is an orally active and blood-brain barrier-permeable selective partial agonist of the human nociceptin/orphanin FQ receptor (NOP), which exhibits high affinity for human targets (K_i=3.3 nM; EC₅₀=4.03 nM; E_max=47.8%) without activating μ and κ opioid receptors. Sunobinop significantly reduces wakefulness time and increases non-rapid eye movement sleep in rats by activating NOP receptors, and produces no significant side effects on learning, memory, reward, respiration or intestinal function at effective doses. Sunobinop displays competitive antagonist properties in specific signaling pathways, such as β-arrestin 2 recruitment. With these unique pharmacological properties, Sunobinop can be used to investigate insomnia, moderate-to-severe alcohol use disorder, and urinary incontinence caused by overactive bladder .

HY-101260

DORA-22	Orexin Receptor (OX Receptor)	Neurological Disease
DORA-22 is an orally active dual orexinergic receptor antagonist, and improves the sleep disruption and memory impairment. DORA-22 can be used for study of insomnia .

HY-135359

RP 48497	Drug Metabolite	Neurological Disease
RP 48497, an impurity of Eszopiclone, is a photodegradation product of Eszopiclone. Eszopiclone is a non-benzodiazepine agent used in the treatment of insomnia .

HY-A0014S

Ramelteon-d5 TAK-375-d₅	Isotope-Labeled Compounds Melatonin Receptor	Neurological Disease Endocrinology Cancer
Ramelteon-d₅ is deuterium labeled Ramelteon. Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with K_i values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation .

HY-N7325

Valerosidate	PTEN Orexin Receptor (OX Receptor)	Others
Valerosidate is a Iridoids product that can be isolated from the herbs of Valeriana jatamansi. Valerosidate exhibites inhibitory effects on cell viability and migration in HCT116 cells via increasing the expressions of tumor suppressors (p53 and PTEN) Valerosidate is a natural orexin 2 receptor antagonist and can be used for the study of insomnia.

HY-123737

MK-8133	Orexin Receptor (OX Receptor)	Neurological Disease
MK-8133 is an orexin-2 receptor antagonist. MK-8133 can be used in the study of insomnia .

HY-136922

Orexin receptor antagonist 2	Orexin Receptor (OX Receptor)	Neurological Disease
Orexin receptor antagonist 2 (compound 30) is a potent orexin receptor antagonist with pK_is of 7.69 and 9.78. Orexin receptor antagonist 2 has the potential for the research of insomnia .

HY-15130R

DL-O-Phosphoserine (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
Jujuboside A (Standard) is the analytical standard of Jujuboside A. This product is intended for research and analytical applications. Jujuboside A is a glycoside extracted from Semen Ziziphi Spinosae, a Chinese herbal medicine used to treat insomnia and anxiety.

HY-177085

Fumiporexant	Orexin Receptor (OX Receptor)	Neurological Disease
Fumiporexant (Compound Example 93) is an orally active, brain-penetrant and selective Orexin receptor 2 (OX2R) antagonist. Fumiporexant regulates the sleep-wake cycle and emotion-related pathways in the central nervous system. Fumiporexant is promising for research of nervous system diseases such as insomnia and major depressive disorder .

HY-106136

TIK-301 PD-6735; LY-156735	Melatonin Receptor 5-HT Receptor	Neurological Disease
TIK-301 (PD-6735) is a chlorinated melatonin derivative and a potent, high-affinity and orally active melatonin MT₁ and MT₂ receptors agonist with K_is of 0.081 nM and 0.042 nM, respectively. TIK-301 is also a 5-HT_2B/5-HT_2C receptors antagonist with antidepressant action. TIK-301 has the potential for sleep disorders and other circadian rhythm disorders treatment .

HY-W039283

MCH-1 antagonist 2	MCHR1 (GPR24)	Neurological Disease Cancer
MCH-1 antagonist 2 (l-BROMO-2,4-DIFLUORO-5-NITROBEN-ZENE) is a melanin concentrating hormone-1 (MCH1) receptor-selective 4-aryl piperidine. MCH-1 antagonist 2 can be used for the research of depression, anxiety, obesity, urge incontinence, urinary incontinence, major depression, bipolar disorder, agoraphobia, specific phobia, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder, acute stress disorder, urinary frequency, urinary urgency, nocturia, enuresis, bulimia, bulimia nervosa, anorexia nervosa, major depressive disorder, dysthymic disorder, bipolar 1 and 2 disorders, schizoaffective disorder, cognitive disorders with depressed mood, personality disorders, insomnia, hypersomnia, narcolepsy, circadian rhythm sleep disorder, nightmare disorder, sleep terror disorder, sleepwalking disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, overactive bladder .

HY-N16466

Valerenal Nardal	Drug Derivative	Neurological Disease
Valerenal (Nardal) is a sesquiterpene found in Valeriana officinalis root oil. Valerian root can be used as an herbal sedative which is helpful in the treatment of insomnia .

HY-113555

DORA 42	Orexin Receptor (OX Receptor)	Neurological Disease
DORA 42 is a dual orexin 1 and orexin 2 receptor antagonist with sleep efficacy in rats. DORA 42 is promising for research of insomnia .

HY-103522

AA29504	GABA Receptor	Neurological Disease
AA29504 is a ethyl carbamate with γ-aminobutyric acid (GABAA(HY-L120) receptor activity. AA29504 inhibits the delivery of the neurotransmitter gamma-aminobutyric acid in the central nervous system. AA29504 can be used to research anxiety, insomnia and other neuropsychiatric diseases .

HY-16505

Triclofos sodium	Endogenous Metabolite	Neurological Disease
Triclofos sodium is a drug used to suppress insomnia and for sedation and has sedative activity. Triclofos sodium is used in children for sedation during painless medical procedures, particularly in children with neurocognitive disorders. Triclofos sodium has similar physiological and pharmacological properties to chloral and therefore can be used as a substitute when necessary. The safety and efficacy of Triclofos sodium have been demonstrated in pediatric populations with high rates of neurocognitive disorders .

HY-A0069A

Doxylamine	Histamine Receptor Cytochrome P450	Neurological Disease Metabolic Disease
Doxylamine is a first-generation antihistamine and acts as a histamine H1 receptor antagonist. Doxylamine is orally active, possessing analgesic and hypnotic activities. Doxylamine enhances the activities of CYP2B, CYP2A, CYP3A and thyroxine-glucuronosyltransferase via promoting substrate hydroxylation and thyroxine metabolic pathways. Doxylamine decreases serum thyroxine (T4) level and elevates serum thyroid-stimulating hormone (TSH) level. Doxylamine induces liver enlargement and increases the activities of hepatic microsomal cytochrome P450, cytochrome b5 and NADPH-cytochrome c reductase. Doxylamine can be used for the research of nausea, allergy, insomnia .

HY-A0069R

Doxylamine succinate (Standard)	Reference Standards Histamine Receptor Cytochrome P450	Neurological Disease Metabolic Disease
Doxylamine succinate (Standard) is the analytical standard of Doxylamine succinate (HY-A0069). This product is intended for research and analytical applications. Doxylamine succinate is a first-generation antihistamine and acts as a histamine H1 receptor antagonist. Doxylamine succinate is orally active, possessing analgesic and hypnotic activities. Doxylamine succinate enhances the activities of CYP2B, CYP2A, CYP3A and thyroxine-glucuronosyltransferase via promoting substrate hydroxylation and thyroxine metabolic pathways. Doxylamine succinate decreases serum thyroxine (T4) level and elevates serum thyroid-stimulating hormone (TSH) level. Doxylamine succinate induces liver enlargement and increases the activities of hepatic microsomal cytochrome P450, cytochrome b5 and NADPH-cytochrome c reductase. Doxylamine succinate can be used for the research of nausea, allergy, insomnia .

HY-A0232

Heptabarbital Medomin	Drug Derivative	Neurological Disease
Heptabarbital (Medomin) is an oral activity Barbituric acid derivative. Heptabarbital has the potential for the research of insomnia .

HY-115139

Fenadiazole	Others	Neurological Disease
Fenadiazole acts as a central nervous system agent to manage insomnia and dreaminess .

HY-A0014R

Ramelteon (Standard) TAK-375 (Standard)	Reference Standards Melatonin Receptor	Neurological Disease Endocrinology Cancer
Ramelteon (Standard) is the analytical standard of Ramelteon. This product is intended for research and analytical applications. Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation .

HY-U00051A

Propiomazine hydrochloride	Histamine Receptor	Neurological Disease
Propiomazine hydrochloride is an orally active antihistamine agent. Propiomazine hydrochloride is a potent prolactin (PRL) release stimulant, whose effect depends on the antagonism of the dopaminergic system and can inhibit the secretion of luteinizing hormone (LH). Propiomazine hydrochloride is mainly used for anesthesia assistance, mental disorders and anxiety-induced sedation, and can also be used in research related to insomnia .

HY-101629

(E)-Crotylbarbital	Drug Intermediate	Neurological Disease
(E)-Crotylbarbital is the isomer of Crotylbarbital. Crotylbarbital is a barbiturate derivative and can be used for the research of insomnia.

HY-W518478

Zolpyridine	Drug Metabolite	Others
Zolpyridine is a degradation product of Zolpidem tartrate .

HY-12140

Vestipitant GW597599	Neurokinin Receptor	Neurological Disease
Vestipitant (GW597599) is a neurokinin-1 receptor antagonist (pKi: 9.4, hNK1) with hypnotic effects and the ability to suppress primary insomnia. Vestipitant can effectively block substance P-mediated extracellular regulated kinase phosphorylation and relieve anxiety and possible depression induced by the agonist GR73632 (HY-P1192) in gerbils. Vestipitant can also improve functional dyspnea, anxiety, insomnia, irritable bowel disease, gastroesophageal reflux disease, tinnitus and antiemetic effects .

HY-N0659R

Jujuboside A (Standard)	Reference Standards GABA Receptor	Neurological Disease
Jujuboside A (Standard) is the analytical standard of Jujuboside A. This product is intended for research and analytical applications. Jujuboside A is a glycoside extracted from Semen Ziziphi Spinosae, a Chinese herbal medicine used to treat insomnia and anxiety.

HY-135359R

RP 48497 (Standard)	Drug Metabolite Reference Standards	Neurological Disease
Adenosine 5'-monophosphate (disodium) (Standard) is the analytical standard of Adenosine 5'-monophosphate (disodium). This product is intended for research and analytical applications. Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes .

HY-129105R

Clomethiazole (Standard)	GABA Receptor Cytochrome P450 Reference Standards	Neurological Disease
Clomethiazole (Standard) is the analytical standard of Clomethiazole. This product is intended for research and analytical applications. Chlormethiazole is an potent and orally active GABAA agonist . Chlormethiazole inhibits cytochrome P450 isoforms: CYP2A6 and CYP2E1 in human liver microsomes. Chlormethiazole is an anticonvulsant agent and has the potential for treating convulsive status epilepticus .

HY-U00051AS1

(R)-Propiomazine-d6 hydrochloride	Isotope-Labeled Compounds	Neurological Disease
(R)-Propiomazine-d₆ hydrochloride is deuterium labeled Propiomazine hydrochloride. Propiomazine hydrochloride is an orally active antihistamine agent. Propiomazine hydrochloride is a potent prolactin (PRL) release stimulant, whose effect depends on the antagonism of the dopaminergic system and can inhibit the secretion of luteinizing hormone (LH). Propiomazine hydrochloride is mainly used for anesthesia assistance, mental disorders and anxiety-induced sedation, and can also be used in research related to insomnia.

HY-U00051AS

Propiomazine-d6 hydrochloride	Isotope-Labeled Compounds Histamine Receptor	Neurological Disease
Propiomazine-d₆ hydrochloride is deuterium labeled Propiomazine hydrochloride. Propiomazine hydrochloride is an orally active antihistamine agent. Propiomazine hydrochloride is a potent prolactin (PRL) release stimulant, whose effect depends on the antagonism of the dopaminergic system and can inhibit the secretion of luteinizing hormone (LH). Propiomazine hydrochloride is mainly used for anesthesia assistance, mental disorders and anxiety-induced sedation, and can also be used in research related to insomnia.

HY-U00051AS2

(S)-Propiomazine-d6 hydrochloride	Isotope-Labeled Compounds	Neurological Disease
(S)-Propiomazine-d₆ hydrochloride is deuterium labeled Propiomazine hydrochloride. Propiomazine hydrochloride is an orally active antihistamine agent. Propiomazine hydrochloride is a potent prolactin (PRL) release stimulant, whose effect depends on the antagonism of the dopaminergic system and can inhibit the secretion of luteinizing hormone (LH). Propiomazine hydrochloride is mainly used for anesthesia assistance, mental disorders and anxiety-induced sedation, and can also be used in research related to insomnia.

HY-138110

Toladryl 4-Methyldiphenhydramine	Endogenous Metabolite iGluR Histamine Receptor	Neurological Disease Inflammation/Immunology
Toladryl is a derivative of Diphenhydramine (HY-B0303), capable of penetrating the blood-brain barrier and possessing oral activity, as well as antihistamine and anticholinergic activities. The anticholinergic activity of Toladryl is approximately one-tenth that of Diphenhydramine (HY-B0303), and its protective effect against lethal doses of histamine in guinea pigs is 2 to 4 times that of Diphenhydramine (HY-B0303). The side effects of Toladryl are fewer and milder than those of Diphenhydramine (HY-B0303), but at higher doses, it may cause central nervous system symptoms such as insomnia, agitation, and disorientation. Toladryl can be used for research in allergic diseases .

HY-138110R

Toladryl (Standard) 4-Methyldiphenhydramine (Standard)	Reference Standards Endogenous Metabolite iGluR Histamine Receptor	Neurological Disease Inflammation/Immunology
Toladryl (Standard) is the analytical standard of Toladryl. This product is intended for research and analytical applications. Toladryl is a derivative of Diphenhydramine (HY-B0303), capable of penetrating the blood-brain barrier and possessing oral activity, as well as antihistamine and anticholinergic activities. The anticholinergic activity of Toladryl is approximately one-tenth that of Diphenhydramine (HY-B0303), and its protective effect against lethal doses of histamine in guinea pigs is 2 to 4 times that of Diphenhydramine (HY-B0303). The side effects of Toladryl are fewer and milder than those of Diphenhydramine (HY-B0303), but at higher doses, it may cause central nervous system symptoms such as insomnia, agitation, and disorientation. Toladryl can be used for research in allergic diseases .

HY-A0069AS

Doxylamine-d5	Isotope-Labeled Compounds Histamine Receptor Cytochrome P450	Neurological Disease Metabolic Disease
Doxylamine-d₅ is deuterium labeled Doxylamine (HY-A0069A). Doxylamine is a first-generation antihistamine and acts as a histamine H1 receptor antagonist. Doxylamine is orally active, possessing analgesic and hypnotic activities. Doxylamine enhances the activities of CYP2B, CYP2A, CYP3A and thyroxine-glucuronosyltransferase via promoting substrate hydroxylation and thyroxine metabolic pathways. Doxylamine decreases serum thyroxine (T4) level and elevates serum thyroid-stimulating hormone (TSH) level. Doxylamine induces liver enlargement and increases the activities of hepatic microsomal cytochrome P450, cytochrome b5 and NADPH-cytochrome c reductase. Doxylamine can be used for the research of nausea, allergy, insomnia .

Cat. No.	Product Name

HY-L120

GABA Receptor Compound Library

209 compounds

GABA receptors are a class of receptors that respond to the neurotransmitter gamma-aminobutyric acid (GABA), the chief inhibitory neurotransmitter in the vertebrate central nervous system. There are two classes of GABA receptors: GABAA and GABAB. GABAA receptors are ligand-gated ion channels (also known as ionotropic receptors), whereas GABAB receptors are G protein-coupled receptors (also known asmetabotropic receptors). GABA receptors are significant drug targets in the treatment of neuropsychiatric disorders such as epilepsy, insomnia, and anxiety, as well as in anesthesia in surgical operations.

MCE offers a unique collection of 209 GABA receptors inhibitors and activators, which is an efficient tool for neuropsychiatric disorders drugs discovery.

Cat. No.	Product Name	Target	Research Area

HY-P1341

OXA(17-33) Orexin A (17-33) (human, mouse, rat, bovine)	Orexin Receptor (OX Receptor) Sigma Receptor Phospholipase	Neurological Disease
OXA (17-33) (Orexin A (17-33) (human, mouse, rat, bovine)) is the shortest active orexin peptide that selectively targets OX1 (EC₅₀=8.29 nM), with 23-fold selectivity for the OX1 receptor over the OX2 receptor. The activity of OXA (17-33) depends on the Tyr17, Leu20, Asn25, His26 residues and the spatial conformation of the α-helix. OXA (17-33) activates signaling pathways involving inositol-1,4,5-trisphosphate receptor (IP3R), phospholipase D (PL-D) and choline-Sigma-1R, thereby increasing the cytoplasmic Ca ²⁺ level in nucleus accumbens neurons, an effect that is blocked by Sigma-1R antagonists. OXA (17-33) serves as an important biological probe for investigating the function of the OX1 receptor. OXA (17-33) can be modified via incorporation of mixed disulfide bonds of homocysteine and cysteamine, and is widely used in studies related to insomnia and narcolepsy .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0659

Jujuboside A 4 Publications Verification	Triterpenes Terpenoids Actaea dahurica Turcz. ex Fisch. & C. A. Mey. Plants Rhamnaceae Source Classification	GABA Receptor
Jujuboside A is a glycoside extracted from Semen Ziziphi Spinosae, a Chinese herbal medicine used to treat insomnia and anxiety.

HY-N7325

Valerosidate	Structural Classification Valeriana jatamansi Jones Iridoids Terpenoids Plants Valerianaceae Source Classification	PTEN Orexin Receptor (OX Receptor)
Valerosidate is a Iridoids product that can be isolated from the herbs of Valeriana jatamansi. Valerosidate exhibites inhibitory effects on cell viability and migration in HCT116 cells via increasing the expressions of tumor suppressors (p53 and PTEN) Valerosidate is a natural orexin 2 receptor antagonist and can be used for the study of insomnia.

HY-15130R

DL-O-Phosphoserine (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Jujuboside A (Standard) is the analytical standard of Jujuboside A. This product is intended for research and analytical applications. Jujuboside A is a glycoside extracted from Semen Ziziphi Spinosae, a Chinese herbal medicine used to treat insomnia and anxiety.

HY-N16466

Valerenal Nardal	Structural Classification Ketones, Aldehydes, Acids Valeriana officinalis Linn. Plants Valerianaceae Source Classification	Drug Derivative
Valerenal (Nardal) is a sesquiterpene found in Valeriana officinalis root oil. Valerian root can be used as an herbal sedative which is helpful in the treatment of insomnia .

HY-N0659R

Jujuboside A (Standard)	Triterpenes Structural Classification Terpenoids Actaea dahurica Turcz. ex Fisch. & C. A. Mey. Plants Rhamnaceae Source Classification	Reference Standards GABA Receptor
Jujuboside A (Standard) is the analytical standard of Jujuboside A. This product is intended for research and analytical applications. Jujuboside A is a glycoside extracted from Semen Ziziphi Spinosae, a Chinese herbal medicine used to treat insomnia and anxiety.

HY-N18680

Melissa officinalis extract	Structural Classification Extract	Others
Melissa officinalis extract is rich in various bioactive compounds, such as citronellol, geraniol, glycosides, caffeic acid derivatives, flavonoids, and triterpenoids. Melissa officinalis extract can be used in research on conditions such as nervous tension, anxiety, insomnia, and menstrual disorders.

HY-N15436

5-Deoxykievitone	Structural Classification Flavonoids Leguminosae Phaseolus lunatus L. Plants Isoflavones Source Classification	GABA Receptor
5-Deoxykievitone, an isoflavanone found in Phaseolus species, is a GABA receptor modulator. 5-Deoxykievitone potentiates GABA-induced chloride current through α₁β₂γ_2s GABA_A receptors. 5-Deoxykievitone can be used for the research of epilepsy and anxiety .

Cat. No.	Product Name	Chemical Structure

HY-A0014S1

Ramelteon-d3

Ramelteon-d₃ (TAK-375-d₃) is a deuterium-labelled Ramelteon (HY-A0014). Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with K_i values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation.

HY-A0014S

Ramelteon-d5

Ramelteon-d₅ is deuterium labeled Ramelteon. Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with K_i values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation .

HY-U00051AS1

(R)-Propiomazine-d6 hydrochloride

(R)-Propiomazine-d₆ hydrochloride is deuterium labeled Propiomazine hydrochloride. Propiomazine hydrochloride is an orally active antihistamine agent. Propiomazine hydrochloride is a potent prolactin (PRL) release stimulant, whose effect depends on the antagonism of the dopaminergic system and can inhibit the secretion of luteinizing hormone (LH). Propiomazine hydrochloride is mainly used for anesthesia assistance, mental disorders and anxiety-induced sedation, and can also be used in research related to insomnia.

HY-U00051AS

Propiomazine-d6 hydrochloride

Propiomazine-d₆ hydrochloride is deuterium labeled Propiomazine hydrochloride. Propiomazine hydrochloride is an orally active antihistamine agent. Propiomazine hydrochloride is a potent prolactin (PRL) release stimulant, whose effect depends on the antagonism of the dopaminergic system and can inhibit the secretion of luteinizing hormone (LH). Propiomazine hydrochloride is mainly used for anesthesia assistance, mental disorders and anxiety-induced sedation, and can also be used in research related to insomnia.

HY-U00051AS2

(S)-Propiomazine-d6 hydrochloride

(S)-Propiomazine-d₆ hydrochloride is deuterium labeled Propiomazine hydrochloride. Propiomazine hydrochloride is an orally active antihistamine agent. Propiomazine hydrochloride is a potent prolactin (PRL) release stimulant, whose effect depends on the antagonism of the dopaminergic system and can inhibit the secretion of luteinizing hormone (LH). Propiomazine hydrochloride is mainly used for anesthesia assistance, mental disorders and anxiety-induced sedation, and can also be used in research related to insomnia.

HY-A0069AS

Doxylamine-d5

Doxylamine-d₅ is deuterium labeled Doxylamine (HY-A0069A). Doxylamine is a first-generation antihistamine and acts as a histamine H1 receptor antagonist. Doxylamine is orally active, possessing analgesic and hypnotic activities. Doxylamine enhances the activities of CYP2B, CYP2A, CYP3A and thyroxine-glucuronosyltransferase via promoting substrate hydroxylation and thyroxine metabolic pathways. Doxylamine decreases serum thyroxine (T4) level and elevates serum thyroid-stimulating hormone (TSH) level. Doxylamine induces liver enlargement and increases the activities of hepatic microsomal cytochrome P450, cytochrome b5 and NADPH-cytochrome c reductase. Doxylamine can be used for the research of nausea, allergy, insomnia .

HY-A0069S

Doxylamine-d5 succinate

Doxylamine-d₅ succinate is deuterium labeled Doxylamine succinate (HY-A0069A). Doxylamine succinate is a first-generation antihistamine and acts as a histamine H1 receptor antagonist. Doxylamine succinate is orally active, possessing analgesic and hypnotic activities. Doxylamine succinate enhances the activities of CYP2B, CYP2A, CYP3A and thyroxine-glucuronosyltransferase via promoting substrate hydroxylation and thyroxine metabolic pathways. Doxylamine succinate decreases serum thyroxine (T4) level and elevates serum thyroid-stimulating hormone (TSH) level. Doxylamine succinate induces liver enlargement and increases the activities of hepatic microsomal cytochrome P450, cytochrome b5 and NADPH-cytochrome c reductase. Doxylamine succinate can be used for the research of nausea, allergy, insomnia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks